Evidence map›Paper›PMID 24039426›Full record

ArticleInternational journal of nanomedicine2013

Photothermal ablation of pancreatic cancer cells with hybrid iron-oxide core gold-shell nanoparticles.

Yang Guo, Zhuoli Zhang, Dong-Hyun Kim, Weiguo Li, Jodi Nicolai, Daniel Procissi, Yi Huan, Guohong Han, Reed A Omary, Andrew C Larson

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 63 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Targeted Photothermal Therapy of Melanoma in C57BL/6 Mice using FeJournal of biomedical physics & engineering · 2021
    Article
  6. Review
  7. Article
  8. The use of nanoparticulates to treat breast cancer.Nanomedicine (London, England) · 2017
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Size- and Shape-Controlled Synthesis and Properties of Magnetic-Plasmonic Core-Shell Nanoparticles.The journal of physical chemistry. C, Nanomaterials and interfaces · 2016
    Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Yang GuoDepartment of Radiology, Northwestern University, Chicago, IL, USA.
Zhuoli Zhang
Dong-Hyun Kim
Weiguo Li
Jodi Nicolai
Daniel Procissi
Yi Huan
Guohong Han
Reed A Omary
Andrew C Larson
Northwestern University · USIndo-American Center · USXijing Hospital · CN

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
Quantitative MRI-Guided Nanoembolization for Liver CancerR01CA159178 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LARSON, ANDREW CHRISTIAN, OMARY, REED A. · 2011 to 2015
$2.4M
MRI of Iron-labeled Microsphere Biodistribution for Radioembolization DosimetryR01CA141047 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LARSON, ANDREW CHRISTIAN · 2010 to 2013
$1.2M
NCI NIH HHS CA141047NCI NIH HHS CA159178NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA141047NCI NIH HHS R01 CA159178
6 · The paper itself

Abstract

purposePhotothermal ablation is a minimally invasive approach, which typically involves delivery of photothermal sensitizers to targeted tissues. The purpose of our study was to demonstrate that gold nanoparticles are phagocytosed by pancreatic cancer cells, thus permitting magnetic resonance imaging (MRI) of sensitizer delivery and photothermal ablation. PATIENTS AND

methodsIron-oxide core/gold-shell nanoparticles (GoldMag®, 30 nm diameter; Xi'an GoldMag Biotechnology Co, Xi'an, People's Republic of China) were used. In a 96-well plate, 3 × 10⁴ PANC-1 (human pancreatic cancer cell line) cells were placed. GoldMag (0, 25, or 50 μg/mL) was added to each well and 24 hours allowed for cellular uptake. Samples were then divided into two groups: one treated with photothermal ablation (7.9 W/cm²) for 5 minutes, the other not treated. Photothermal ablation was performed using laser system (BWF5; B&W Tek, Inc, Newark, DE, USA). Intraprocedural temperature changes were measured using a fiber optic temperature probe (FTP-LN2; Photon Control Inc, Burnaby, BC, Canada). After 24 hours, the remaining number of viable cells was counted using trypan blue staining; cell proliferation percentage was calculated based on the total number of viable cells after treatment compared with control. MRI of GoldMag uptake was performed using a 7.0T ClinScan system (Bruker BioSpin, Ettlingen, Germany).

resultsTemperature curves demonstrated that with increased GoldMag uptake, laser irradiation produced higher temperature elevations in the corresponding samples; temperature elevations of 12.89°C, 35.16°C, and 79.51°C were achieved for 0, 25, and 50 μg/mL GoldMag. Without photothermal ablation, the cell proliferation percentage changed from 100% to 71.3% and 47.0% for cells treated with 25 and 50 μg/mL GoldMag. Photothermal ablation of PANC-1 cells demonstrated an effective treatment response, specifically a reduction to only 61%, 21.9%, and 2.3% cell proliferation for cells treated with 0, 25, and 50 μg/mL GoldMag. MRI was able to visualize GoldMag uptake within PANC-1 cells.

conclusionOur findings suggest that photothermal ablation may be effective in the treatment of pancreatic cancer. GoldMag nanoparticles could serve as photothermal sensitizers, and MRI is feasible to quantify delivery.

Indexed as

ApoptosisCell Line, TumorCell SurvivalGoldHumansHyperthermia, InducedLightMagnetite NanoparticlesPancreatic NeoplasmsPhotosensitizing AgentsPhototherapyTreatment OutcomeGoldMagnetite NanoparticlesPhotosensitizing Agentshybrid nanoparticlesmagnetic resonance imagingphotothermal ablation therapy

Identifiers

PMID24039426
PMCPMC3771851
OpenAlexW2047988521

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.